Drug
NC410
NC410 is a pharmaceutical drug with 3 clinical trials. Currently 2 active trials ongoing.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Completion Rate
0%(0/1)
Active Trials
2(67%)
Terminated
1(33%)
Phase Distribution
Ph phase_1
2
67%
Ph phase_2
1
33%
Phase Distribution
2
Early Stage
1
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
2(66.7%)
Phase 2Efficacy & side effects
1(33.3%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
0.0%
0 of 1 finished
Non-Completion Rate
100.0%
1 ended early
Currently Active
2
trials recruiting
Total Trials
3
all time
Status Distribution
Active(2)
Terminated(1)
Detailed Status
Recruiting1
Terminated1
Active, not recruiting1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
2
Success Rate
0.0%
Most Advanced
Phase 2
Trials by Phase
Phase 12 (66.7%)
Phase 21 (33.3%)
Trials by Status
recruiting133%
terminated133%
active_not_recruiting133%
Recent Activity
2 active trials
Showing 3 of 3
recruitingphase_2
NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer
NCT06941857
active_not_recruitingphase_1
A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants with Advanced Unresectable or Metastatic Solid Tumors
NCT05572684
terminatedphase_1
A Safety and Tolerability Study of NC410 in Subjects With Advanced or Metastatic Solid Tumors
NCT04408599
Clinical Trials (3)
Showing 3 of 3 trials
NCT06941857Phase 2
NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer
NCT05572684Phase 1
A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants with Advanced Unresectable or Metastatic Solid Tumors
NCT04408599Phase 1
A Safety and Tolerability Study of NC410 in Subjects With Advanced or Metastatic Solid Tumors
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3